• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • TheStreet Smarts
  1. Home
  2. / Investing
  3. / Stocks

Crispr Therapeutics Gets an Upgrade but Needs Help on the Charts

The shares have been correcting since July.
By BRUCE KAMICH
Oct 05, 2020 | 02:23 PM EDT
Stocks quotes in this article: CRSP

Cutting-edge Crispr Therapeutics (CRSP) was upgraded Monday by a major sell-side firm. The stock is up on the day but it pays to check out the charts and indicators. I never forget the old Middle-Eastern saying, "If you truly seek wisdom you will visit all of the tents in the marketplace."

Let's check out the charts. 

In the daily bar chart of CRSP, below, we can see that the shares have been correcting since July. CRSP really peaked in early July even though prices temporarily pushed up to a new high in August. Prices broke below the cresting 50-day moving average line in early September and are testing the underside of the declining average line now. The 200-day moving average line is rising and well below the current price action.

The On-Balance-Volume (OBV) line rose from March to early July and then turned lower. The OBV line is still pointed down telling us that sellers of CRSP have been more aggressive. The Moving Average Convergence Divergence (MACD) oscillator is below the zero in sell territory.

 
In the weekly bar chart of CRSP, below, we can see a mixed picture. Prices are in an uptrend above the rising 40-week moving average line but CRSP has been correcting.
 
The weekly OBV line has been rising from late 2018 but shows some weakness in the past couple of months. The MACD oscillator has crossed to the downside for a take profits sell signal. 
 
 
 
In this daily Point and Figure chart of CRSP, below, we can see a potential upside price target in the $102 area. 
 
 
Bottom-line strategy: I am not yet convinced that CRSP can rally strongly BUT a close above $89 tells me that traders could go long risking a close below $80. Take profits around $102 if available.
 
Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

Employees of TheStreet are prohibited from trading individual securities.

TAGS: Investing | Stocks | Technical Analysis | Biotechnology | Analyst Actions

More from Stocks

Kohl's Charts Continue to Decline

Bruce Kamich
May 31, 2023 12:30 PM EDT

Here's what to avoid.

Finding Value in a 'Unique' Niche of the Healthcare Sector

Bret Jensen
May 31, 2023 11:30 AM EDT

Insider buying by the new CEO of this buyer of biopharmaceutical royalties, puts this name on my radar.

There's a Significant Change in the Market's Character

James "Rev Shark" DePorre
May 31, 2023 11:11 AM EDT

The AI frenzy is taking a rest, and the number of stocks that are attracting speculative interest is very slim.

Advance Auto Parts Results Were U-G-L-Y: Is the Stock a Lemon Too?

Stephen Guilfoyle
May 31, 2023 10:30 AM EDT

This balance sheet needs a lot of work.

The Chase Is Not On

Guy Ortmann
May 31, 2023 9:31 AM EDT

Here's why we would wait for better buying opportunities.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 12:07 PM EDT STEPHEN GUILFOYLE

    Selling Some of This Surging AI-Related Stock

    This isn't the only name in the Stocks Under $10 p...
  • 09:48 AM EDT CHRIS VERSACE

    Latest AAP Podcast With Portillo's CEO!

    Listen in as we talk with a rising star in the Chi...
  • 03:25 PM EDT JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    Don't Just Sit There and 'Hope' for Your Stocks, M...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2023 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login